These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25495991)

  • 1. Therapeutic effects of GM1 on Parkinson's disease in rats and its mechanism.
    Ba XH
    Int J Neurosci; 2016; 126(2):163-7. PubMed ID: 25495991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of interleukin-1 receptor 1 is not neuroprotective in the 6-hydroxydopamine striatal lesion rat model of Parkinson's disease.
    Walsh S; Gavin A; Wyatt S; O'Connor C; Keeshan K; Nolan YM; O'Keeffe GW; Sullivan AM
    Int J Neurosci; 2015 Jan; 125(1):70-7. PubMed ID: 24628580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons.
    Frau L; Morelli M; Simola N
    Exp Neurol; 2013 Sep; 247():663-72. PubMed ID: 23499830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Place conditioning to apomorphine in rat models of Parkinson's disease: differences by dose and side-effect expression.
    Campbell JC; Jeyamohan SB; De La Cruz P; Chen N; Shin D; Pilitsis JG
    Behav Brain Res; 2014 Dec; 275():114-9. PubMed ID: 25205367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
    Yuan H; Sarre S; Ebinger G; Michotte Y
    Brain Res; 2004 Nov; 1026(1):95-107. PubMed ID: 15476701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BDNF receptor blockade hinders the beneficial effects of exercise in a rat model of Parkinson's disease.
    Real CC; Ferreira AF; Chaves-Kirsten GP; Torrão AS; Pires RS; Britto LR
    Neuroscience; 2013 May; 237():118-29. PubMed ID: 23396085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β.
    Muñoz A; Garrido-Gil P; Dominguez-Meijide A; Labandeira-Garcia JL
    Exp Neurol; 2014 Nov; 261():720-32. PubMed ID: 25160895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of interleukin-10 on expression of inflammatory mediators and anti-inflammatory mediators during acute lung injury in rats].
    Li HX; Zhang JC; Zhao YL; Hao HJ
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2005 Jun; 17(6):338-41. PubMed ID: 15970097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of estrogen on temporal expressions of IL-1beta and IL-1ra in rat organotypic hippocampal slices exposed to oxygen-glucose deprivation.
    Choi JS; Kim SJ; Shin JA; Lee KE; Park EM
    Neurosci Lett; 2008 Jun; 438(2):233-7. PubMed ID: 18455872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal imbalance of interleukin-1β and interleukin-1 receptor antagonist in canine inflammatory bowel disease.
    Maeda S; Ohno K; Nakamura K; Uchida K; Nakashima K; Fukushima K; Tsukamoto A; Goto-Koshino Y; Fujino Y; Tsujimoto H
    Vet J; 2012 Oct; 194(1):66-70. PubMed ID: 22483380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
    Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.
    Han B; Jin HJ; Song MY; Wang T; Zhao H
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1191-5. PubMed ID: 25219971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression.
    Duty S; Brotchie JM
    Exp Neurol; 1997 Apr; 144(2):423-32. PubMed ID: 9168843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding.
    Schneider JS; Cambi F; Gollomp SM; Kuwabara H; Brašić JR; Leiby B; Sendek S; Wong DF
    J Neurol Sci; 2015 Sep; 356(1-2):118-23. PubMed ID: 26099170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect and mechanism on dopamine contents of striatum in rat model of Parkinson's disease ginsenoside Rg1].
    Xu L; Liu LX; Chen WF
    Zhongguo Zhong Yao Za Zhi; 2008 Aug; 33(15):1856-9. PubMed ID: 19007016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions.
    Machado-Filho JA; Correia AO; Montenegro AB; Nobre ME; Cerqueira GS; Neves KR; Naffah-Mazzacoratti Mda G; Cavalheiro EA; de Castro Brito GA; de Barros Viana GS
    Behav Brain Res; 2014 May; 264():116-25. PubMed ID: 24525422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.